<DOC>
	<DOCNO>NCT00954941</DOCNO>
	<brief_summary>The goal clinical research study compare effectiveness receive combination ondansetron aprepitant receive ondansetron alone help prevent nausea and/or vomit patient Acute myeloid leukemia ( AML ) high-risk ( HR ) Myelodysplastic syndrome ( MDS ) receive cytarabine . The safety drug combination also study .</brief_summary>
	<brief_title>Ondansetron Versus Aprepitant Plus Ondansetron Emesis</brief_title>
	<detailed_description>Cytarabine drug use treat AML high-risk MDS . It known cause nausea and/or vomit . All patient receive cytarabine also receive drug help prevent side effect . The Study Drugs : Ondansetron design block action serotonin , substance brain cause chemotherapy-related nausea vomit . Aprepitant design block different natural substance brain cause chemotherapy-related nausea vomit . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 group . You equal chance either group . If Group 1 , receive ondansetron . If Group 2 , receive ondansetron aprepitant . Study Drug Administration : Both group receive ondansetron vein 30 minute receive chemotherapy 6 to12 hour chemotherapy . The length chemotherapy infusion different patient . If Group 2 , addition ondansetron , take 1 capsule aprepitant every morning receive chemotherapy . You take last dose aprepitant day chemotherapy infusion complete . If miss dose aprepitant , take soon remember . Study Diary : You fill study diary every day 7 day chemotherapy . You record often experience nausea and/or vomit time need medication study . It take 5 minute complete time . Length Study : You study 7 day . You take study intolerable side effect occur . Blood Draws : Blood ( 1 teaspoon ) drawn routine test last dose ( +/- 3 day ) study drug . This investigational study . Ondansetron aprepitant FDA approve commercially available prevention chemotherapy-related nausea vomiting . Using drug combination investigational . Up 100 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Patients great equal 18 year age . 2 . Patients diagnosis acute myelogenous leukemia , highrisk myelodysplastic syndrome , chronic myelogenous leukemia blast crisis acute undifferentiated leukemia receive chemotherapy regimen contain highdose cytarabine ( great equal 1g/m^2/d least 3 day ) . 3 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 1 . Patients emesis grade 2 3 nausea present less equal 24 hour chemotherapy . 2 . Patients ongoing emesis due organic etiology 3 . Patients know hypersensitivity study drug 5HT3 receptor antagonist 4 . Patients receive pimozide , terfenadine , astemizole , cisapride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hematologic Disorder</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>High-risk myelodysplastic syndrome</keyword>
	<keyword>HR-MDS</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Zofran</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Emend</keyword>
	<keyword>L 754030</keyword>
	<keyword>MK 869</keyword>
	<keyword>Emesis</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>